Pulmonx (LUNG) Receivables (2019 - 2025)

Pulmonx (LUNG) has 7 years of Receivables data on file, last reported at $12.1 million in Q4 2025.

• Quarterly Receivables fell 7.99% year-over-year to $12.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.1 million (down 7.99% YoY) and the FY2025 annual result came in at $12.1 million, down 7.99% from the prior year.
• Receivables slipped to $12.1 million in Q4 2025 per LUNG's latest filing, from $13.8 million in the prior quarter.
• Across five years, Receivables topped out at $15.9 million in Q2 2025 and bottomed at $5.1 million in Q1 2021.
• The 5-year median for Receivables is $9.5 million (2023), against an average of $9.9 million.
• The widest annual swing landed in 2021, when Receivables jumped 55.2%; it then retreated 7.99% in 2025.
• Tracing LUNG's Receivables over 5 years: stood at $6.6 million in 2021, then soared by 32.23% to $8.7 million in 2022, then jumped by 39.51% to $12.1 million in 2023, then climbed by 8.38% to $13.1 million in 2024, then declined by 7.99% to $12.1 million in 2025.
• Per Business Quant, the three latest LUNG Receivables figures stand at $12.1 million (Q4 2025), $13.8 million (Q3 2025), and $15.9 million (Q2 2025).

Peer Comparison